Calcium effects on epidermal growth factor receptor-mediated endocytosis in normal and SV40-transformed human fibroblasts
✍ Scribed by Joseph T. Tupper; Peter V. Bodine
- Publisher
- John Wiley and Sons
- Year
- 1983
- Tongue
- English
- Weight
- 786 KB
- Volume
- 115
- Category
- Article
- ISSN
- 0021-9541
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Lowering of extracellular Ca^2+^ levels will reversibly arrest the growth of human fibroblasts (WI38). Simian virus~40~(SV~40~)‐transformed WI38 cells do not exhibit this Ca^2+^‐dependent arrest. One possibility for this difference in Ca^2+^ requirement is that extracellular or surface membrane‐bound Ca^2+^ may be required for growth factor receptor‐mediated endocytosis and this Ca^2+^ requirement may differ in normal versus transformed cells. In this study we have evaluated the role of Ca^2+^ in the binding, internalization, and degradation of epidermal growth factor (EGF) in the WI38 and SV~40~ WI38 cell. The binding of [^125^I]EGF to the cell surface is not significantly altered by lowering of Ca^2+^ to 10^−5^‐M levels in either the normal or transformed cell. At this Ca^2+^ level, growth of the normal cell is inhibited. The subsequent internalization of EGF is reduced nearly threefold in the normal cell but not in the transformed cell following Ca^2+^ deprivation. Degradation of the EGF‐receptor complex is also sensitive to Ca^2+^. A twofold reduction in the rate of release of acid‐soluble ^125^I occurs in the normal but not the transformed cell under conditions of lowered medium Ca^2+^. In contrast, 2‐chloro‐10‐3‐aminopropyl phenothiazine (CP), an inhibitor of the Ca^2+^‐dependent regulator protein calmodulin, causes an inhibition of [^125^I]EGF internalization and degradation in both the normal and transformed WI38 cell, and a marked inhibition of [^125^I]EGF binding to the cell surface receptor of the transformed cell but not the normal cell.
📜 SIMILAR VOLUMES
## Abstract We previously reported that expression of angiogenesis factors interleukin‐8 (IL‐8) and vascular endothelial growth factor (VEGF) is promoted by coactivation of transcription factors nuclear factor‐kappaB (NF‐κB) and activator protein‐1 (AP‐1) by interleukin‐1α in human head and neck sq